Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034148 | 0.88 | SLC6A2 (0.46) | GPR119CHRM2CHRM1CHRM3USP30 | |
| SCHEMBL12094592 | 0.86 | GPR119 (0.46) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL6491111 | 0.86 | GPR119 (0.46) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL28730740 | 0.85 | CHRM2 (0.42) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL22471536 | 0.85 | CHRM2 (0.42) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL24223887 | 0.85 | CHRM2 (0.42) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL17548160 | 0.85 | KCNK3 (0.43) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL9953059 | 0.81 | MAPT (0.46) | GPR119CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL31030985 | 0.81 | CDK9 (0.42) | GPR119CHRM2CHRM1CHRM3WDR5 | |
| SCHEMBL24212061 | 0.81 | CDK9 (0.42) | GPR119CHRM2CHRM1CHRM3WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897773-B2 | Urea derivatives of tropane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2011-03-01 | — | — | US | disclosed |
| US-20100324084-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-23 | — | — | US | disclosed |
| EP-2046791-B1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2010-03-24 | — | — | EP | disclosed |
| US-20090170894-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | US | disclosed |
| EP-2046791-A2 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi-Aventis (FR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008000951-A2 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170894-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HSD11B1, ADRA1D, HSD17B1 | GPR119 970/4885CHRM2 93/4885CHRM1 59/4885 |
| US-20100324084-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HSD11B1, ADRA1D, HSD17B1 | GPR119 970/4885CHRM2 93/4885CHRM1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.